Literature DB >> 6268139

Familial bleeding tendency with partial platelet thromboxane synthetase deficiency: reorientation of cyclic endoperoxide metabolism.

G Defreyn, S J Machin, L O Carreras, M V Dauden, D A Chamone, J Vermylen.   

Abstract

Three family members from three successive generations presented with a moderate bleeding tendency and a functional platelet defect. They had absent aggregation with arachidonic acid (0.6--3 microM), reversible aggregation with ADP (4 microgram) and cyclic endoperoxide analogues, single wave aggregation only with adrenaline (5.4 microgram) and a prolonged template bleeding time (> min). Malondialdehyde formation was reduced after N-ethylmaleimide stimulation (2--6 nmol/10(9) platelets; control values 8--12 nmol) and serum thromboxane B2 values were reduced (33--101 ng/ml; control values 200--700 ng/ml). When the platelets were incubated with [3H]arachidonic acid the final metabolite of the lipoxygenase pathway (HETE) was produced in normal amounts but the production of thromboxane B2 and HHT was decreased whereas prostaglandin F2a, and E2 and probably D2 were increased. Evidence for enhanced production of prostaglandin D2 was also provided by the rise in the patient's platelet cyclic AMP levels following stimulation with arachidonic acid. The patient's washed platelets stimulated the production of 6-keto PGF 1a by aspirin-pretreated cultured bovine endothelial cells. The plasma levels of 6-keto PGF1a (439--703 pg/ml; normal 181 +/- 46 pg/ml) were raised. The decreased production of thromboxane B2, HHT and malondialdehyde and increased formation of prostaglandin F2a, E2, D2 and of 6-keto PGF1a are compatible with a partial platelet thromboxane synthetase deficiency and reorientation of cyclic endoperoxide metabolism. The markedly prolonged bleeding time would result not only from reduced formation of thromboxane A2 but also from increased production of the aggregation inhibiting prostaglandins PGI2 and PGD2.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6268139     DOI: 10.1111/j.1365-2141.1981.tb07194.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  7 in total

Review 1.  Laboratory investigation of platelet function: a review of methodology.

Authors:  D A Yardumian; I J Mackie; S J Machin
Journal:  J Clin Pathol       Date:  1986-07       Impact factor: 3.411

Review 2.  Introduction: thromboxane in biological systems and the possible impact of its inhibition.

Authors:  M Verstraete
Journal:  Br J Clin Pharmacol       Date:  1983       Impact factor: 4.335

3.  Reorientation of prostaglandin endoperoxide metabolism by a thromboxane synthetase inhibitor: in vitro and clinical observations.

Authors:  J Vermylen; H Deckmyn
Journal:  Br J Clin Pharmacol       Date:  1983       Impact factor: 4.335

4.  Defective platelet aggregation to the calcium ionophore A23187 in a patient with a lifelong bleeding disorder.

Authors:  S J Machin; J P Keenan; B A McVerry
Journal:  J Clin Pathol       Date:  1983-10       Impact factor: 3.411

Review 5.  Understanding the role of prostaglandin E2 in regulating human platelet activity in health and disease.

Authors:  Eitan A Friedman; Martin L Ogletree; Elias V Haddad; Olivier Boutaud
Journal:  Thromb Res       Date:  2015-05-28       Impact factor: 3.944

6.  "In vitro" and "ex vivo" effects of picotamide, a combined thromboxane A2-synthase inhibitor and -receptor antagonist, on human platelets.

Authors:  M Berrettini; M De Cunto; P Parise; S Grasselli; G G Nenci
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 7.  Effect of Prostanoids on Human Platelet Function: An Overview.

Authors:  Steffen Braune; Jan-Heiner Küpper; Friedrich Jung
Journal:  Int J Mol Sci       Date:  2020-11-27       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.